Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Gene Therapy

Shape Therapeutics raises $112 million series B for RNA-based gene therapies

by Megha Satyanarayana
July 23, 2021 | A version of this story appeared in Volume 99, Issue 27

 

Shape Therapeutics has raised $112 million in series B financing to further develop RNA editing and gene-therapy technologies. Shape’s RNA editing technology takes advantage of an enzyme called ADAR in human cells. To create a delivery system for its gene-therapy technology, the company is screening billions of different adeno-associated viruses made in house.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.